. 2020 Apr 30.
doi: 10.1038/s41586-020-2286-9.
Online ahead of print.
Abstract
The novel coronavirus SARS-CoV-2, the causative agent of COVID-19
respiratory disease, has infected over 2.3 million people, killed over
160,000, and caused worldwide social and economic disruption1,2.
There are currently no antiviral drugs with proven clinical efficacy,
nor are there vaccines for its prevention, and these efforts are
hampered by limited knowledge of the molecular details of SARS-CoV-2
infection. To address this, we cloned, tagged and expressed 26 of the 29
SARS-CoV-2 proteins in human cells and identified the human proteins
physically associated with each using affinity-purification mass
spectrometry (AP-MS), identifying 332 high-confidence SARS-CoV-2-human
protein-protein interactions (PPIs). Among these, we identify 66
druggable human proteins or host factors targeted by 69 compounds (29
FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical
compounds).
Screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.
Tästä luettelosta 29. proteiini listassa on PUSL1 , johon ORF8 tekee interaktion.
PUSL1 (Pseudouridine Synthase Like 1) is a Protein Coding gene.
Diseases associated with PUSL1 include Myopathy, Lactic Acidosis, And Sideroblastic Anemia.
Gene Ontology (GO) annotations related to this gene include RNA binding and pseudouridine synthase activity.
An important paralog of this gene is PUS3.
Screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.
Tästä luettelosta 29. proteiini listassa on PUSL1 , johon ORF8 tekee interaktion.
Inga kommentarer:
Skicka en kommentar